The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.
An ultrasensitive biosensor made from the wonder material graphene has been used to detect molecules that indicate an increased risk of developing cancer.
The biosensor has been shown to be more than five times more sensitive than bioassay tests currently in use, and was able to provide results in a matter of minutes, opening up the possibility of a rapid, point-of-care diagnostic tool for patients.
The biosensor has been presented today, 19 September, in IOP Publishing's journal 2D Materials.
To develop a viable bionsensor, the researchers, from the University of Swansea, had to create patterned graphene devices using a large substrate area, which was not possible using the traditional exfoliation technique where layers of graphene are stripped from graphite.
Read the complete story: http://bit.ly/1rhxpVx
SOurce: ScienceDaily
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen